On Dec. 20, 2021, Oragenics announced it had extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that enabled Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant.

The NRC cell expression technologies provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern.